Skip to main content Skip to section navigation Skip to footer
Rezolute, Inc. IR Overview
  • About
    • Our Mission
    • Leadership
    • Board of Directors
  • Our Science
  • Pipeline
    • Overview
    • Congenital Hyperinsulinism
    • Tumor Hyperinsulinism
  • Publications
    • Publications
    • Data Presentations
  • For Patients
  • Join Us
    • Values
    • Benefits
    • Open Positions
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News
    • Events
    • Stock Quote and Chart
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info
  • Contact Us

News

Investors

Investors

  • Overview
  • Corporate Presentation
  • News
  • Events
  • Stock Quote and Chart
  • Historical Data
  • Analyst Coverage
  • SEC Filings
  • Governance
    • Governance Documents
  • Info
May 5, 2025 8:00 am EDT
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
May 1, 2025 8:00 am EDT
Rezolute to Participate in Upcoming Investor Conferences
Apr 25, 2025 4:30 pm EDT
Rezolute, Inc. Announces Closing of Underwritten Offering
Apr 23, 2025 8:05 am EDT
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants
Apr 23, 2025 8:00 am EDT
Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)
Mar 26, 2025 7:30 am EDT
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
Feb 12, 2025 4:05 pm EST
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Feb 4, 2025 8:00 am EST
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Jan 31, 2025 8:00 am EST
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
Jan 7, 2025 8:00 am EST
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 16
  • Next Pagearrow_forward
rss_feed News RSS

Stay Connected

  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
Visit us on LinkedIn Visit us on X Visit us on Facebook
rezolute logo

©2025 Rezolute, Inc.

Explore

  • About
  • Approach
  • Pipeline
  • Publications
  • For Patients
  • Join Us
  • Investors & Media
  • Contact Us

Contact

Corporate Headquarters

275 Shoreline Drive
Suite 500
Redwood City, CA 94065

+1 (650) 206-4507
info@rezolutebio.com

Investor Relations

Oregon Office
2783 NW Lolo Drive
Suite 150
Bend, OR 97703

Legal

  • Terms of Use
  • Privacy Policy
MENU
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Approach
    • Overview
    • Congenital Hyperinsulinism
    • Tumor Hyperinsulinism
    • Additional Programs
  • Pipeline
    • Overview
    • Congenital Hyperinsulinism
    • Tumor Hyperinsulinism
    • Additional Programs
  • Publications
    • Publications
    • Data Presentations
  • For Patients
  • Join Us
    • Values
    • Benefits
    • Open Positions
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News
    • Events
    • Stock Quote and Chart
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info
  • Contact Us